8-K: QT Imaging Reports $1.7 Million in Revenue for Second Quarter 2024, Achieves 51% Gross Margin

QT Imaging announced its second quarter 2024 financial results, highlighted by $1.7 million in revenue and a 51% gross margin, alongside strategic partnerships and expanded distribution.

Summary

• QT Imaging reported $1.7 million in revenue for the second quarter of 2024, a significant increase from $0.1 million in the same period last year and $1.4 million in the previous quarter.
• The company achieved a gross margin of 51% in Q2 2024, compared to 56% in Q1 2024 and an insignificant margin in Q2 2023.
• The decrease in gross margin compared to the previous quarter was due to variability in the weighted average cost of existing inventory.
• The company shipped four Breast Acoustic CTTM scanners during the quarter, three through a strategic distribution partner, bringing the total number of commercial locations offering their technology in the U.S. to five.
• QT Imaging reported a net loss of $1.2 million for the quarter, which includes $2.1 million of non-cash income related to changes in the fair value of warrant, derivative, and earnout liabilities.
• Non-GAAP Adjusted EBITDA was $(2.1) million for the second quarter of 2024, compared to $(0.7) million for the same period in 2023.
• Net cash used in operating activities was $1.0 million for the quarter, compared to $0.5 million in the second quarter of 2023.
• The company has partnered with the University of Oklahoma and OU Health Stephenson Cancer Center to advance research in medical imaging and improve cancer detection and treatment.
• QT Imaging entered into an exclusive distribution agreement with NXC Imaging, Inc. for the U.S. market.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and strategic partnerships, but the net loss and negative EBITDA temper the overall sentiment. The company is making progress but still has financial challenges to overcome.

Positives

• Revenue increased significantly to $1.7 million in Q2 2024, demonstrating strong growth.
• The company achieved a solid gross margin of 51% in Q2 2024.
• The number of commercial locations offering QT Imaging technology in the U.S. increased to five.
• Strategic partnerships with the University of Oklahoma and Vincere Cancer Center were established.
• An exclusive distribution agreement with NXC Imaging, Inc. was secured for the U.S. market.
• The company is making progress in its engineering and clinical feasibility study.
• A study published in Tomography Journal showed that QT Imaging's technology can differentiate breast tissue types and accurately measure glandular and ductal volumes.

Negatives

• The company experienced a net loss of $1.2 million in Q2 2024.
• Non-GAAP Adjusted EBITDA was negative at $(2.1) million for the quarter.
• Net cash used in operating activities was $1.0 million for the quarter.
• Gross margin decreased from 56% in Q1 2024 to 51% in Q2 2024 due to variability in inventory costs.

Risks

• The company's ability to sell and deploy the QT Imaging Breast Acoustic CT Scanner is subject to risks.
• There are risks associated with extending product offerings into new areas or products.
• The company faces risks related to commercializing its technology.
• Unexpected occurrences could deter the full documentation and bring to market plan for products.
• The company is subject to trends and fluctuations in the industry.
• Changes in demand and purchasing volume of customers could impact the company.
• The company is exposed to the unpredictability of suppliers.
• The ability to attract and retain qualified personnel is a risk.
• Changes in domestic and foreign business, market, financial, political, and legal conditions could impact the company.
• The uncertainty of projected financial information is a risk.
• Delays caused by factors outside of the company's control could impact the company.
• The company's ability to successfully receive purchase orders and generate revenue under existing contracts is a risk.
• The company's ability to realize the benefits of strategic partnerships is a risk.
• The company has identified a material weakness in its internal controls over financial reporting.
• The rollout of the business and the timing of expected business milestones are subject to risks.
• The effects of competition on the company's future business are a risk.
• The company's ability to obtain and access financing in the future is a risk.
• The company's ability to pay its debt obligations as they come due is a risk.

Future Outlook

The company plans to deliver its revenue at the same pace in the second half of 2024 as during the first half of the year, with an expected higher gross margin due to the weighted average cost of existing inventory. 2024 is considered a transitional year as the company stabilizes the business and focuses on commercialization anchored in strategic business partnerships.

Management Comments

• QT Imaging's team completed the first full quarter in the life of our young public company.
• We continued to deliver against our plan for the engineering and clinical feasibility study to solidify the intended partnership for large scale manufacturing.
• This reflects our commitment to expanding the medical imaging market opportunities beyond hospitals and imaging centers by supporting direct-to-provider approaches to enable the ability to lower health care costs and increase access via personal medical imaging.
• We are very proud to report on our partnership with the University of Oklahoma (OU) and the OU Health Stephenson Cancer Center to advance and scale innovative research in medical imaging and to improve precision in cancer detection and treatment.

Industry Context

The announcement highlights QT Imaging's efforts to expand its presence in the medical imaging market, particularly in breast cancer detection. The partnerships with cancer centers and the exclusive distribution agreement indicate a strategic focus on commercialization and market penetration. The company's technology, which uses low-frequency sound waves, positions it as a potential alternative to traditional imaging methods like mammography.

Comparison to Industry Standards

• While specific competitor revenue figures are not provided in this document, the $1.7 million revenue for the quarter is a significant increase for QT Imaging compared to its previous performance, indicating growth in a competitive market.
• The 51% gross margin is a positive sign, but it is important to compare this to other medical device companies in the imaging sector. For example, companies like Hologic, which focuses on women's health, often report gross margins in the 60-70% range, suggesting QT Imaging has room for improvement.
• The strategic partnerships with cancer centers and the exclusive distribution agreement are similar to strategies employed by other medical device companies to expand market reach and adoption of their technologies. For example, companies like GE Healthcare and Siemens Healthineers often partner with hospitals and distributors to promote their imaging equipment.
• The focus on direct-to-provider approaches is a trend in the medical device industry, aiming to reduce healthcare costs and increase access to medical imaging. This strategy is also being pursued by companies like Butterfly Network with their portable ultrasound devices.
• The research collaboration with the University of Oklahoma is similar to other medical device companies that partner with academic institutions to validate their technologies and develop new applications. For example, Philips has numerous research collaborations with universities worldwide.

Stakeholder Impact

• Shareholders may view the revenue growth and strategic partnerships positively, but the net loss and negative EBITDA may cause concern.
• Employees may be encouraged by the company's progress and expansion.
• Customers, including healthcare providers and patients, will benefit from increased access to QT Imaging's technology.
• Suppliers may see increased demand for their products and services.
• Creditors will be monitoring the company's financial performance and ability to meet its obligations.

Next Steps

• The company plans to continue its engineering and clinical feasibility study.
• QT Imaging intends to deliver revenue at the same pace in the second half of 2024 as in the first half.
• The company expects a higher gross margin in the second half of 2024 due to the weighted average cost of existing inventory.
• The company will continue to focus on commercialization anchored in strategic business partnerships.

Key Dates

Keywords

QT Imaging, Breast Acoustic CT, Medical Imaging, Cancer Detection, Gross Margin, Revenue, Distribution Agreement, Partnership, EBITDA, Financial Results